TDOC
Teladoc wants to make virtual care feel less clunky
Teladoc just added two AI-powered tools to its Solo platform, and the pitch is pretty simple: help hospitals move faster, juggle less software, and spend more time with patients instead of wrestling with tabs like it’s 2009.
SoloVitals uses a phone or tablet camera to estimate heart rate and respiration rate by reading tiny skin-color changes. That’s remote photoplethysmography, or rPPG, which is a fancy way of saying your smartphone is now moonlighting as a basic medical device. Teladoc says the feature is clinically validated and is already in private preview for select customers, with a broader release expected in December 2026.
The other AI helper: less typing, more treating
The second tool, SoloScribe, is the kind of thing doctors will probably love if it works as advertised. It uses ambient AI to generate structured notes during virtual visits, then sends them into the patient record. In plain English: less clicking, more actual medicine.
Teladoc says SoloScribe is already generally available, and both tools are baked directly into Solo, which is important because hospitals hate adding yet another one-off platform to the tech stack. That’s also where Oracle Health comes in — Teladoc’s Solo platform already integrates with Oracle’s EHR systems, so ORCL gets a cameo here, not a starring role.
Why investors should care
Teladoc is still fighting the “show me” battle. The stock has been bruised, the trend is weak, and the market clearly isn’t handing out gold stars for AI branding alone. But if Solo becomes the kind of workflow glue that hospitals actually adopt, it could help Teladoc deepen relationships and make its platform harder to rip out.
That’s the bull case: more utility, more stickiness, more reasons for customers to keep paying. The bear case: clever features, weak monetization, and another nice-looking press release that doesn’t budge the chart.
Big picture: Teladoc is trying to turn telehealth from a video-call box into a workflow layer. If the company can make that leap, the upside is real. If not, well, it’s still just another app with a medical voice and a very patient CFO.